Definium Therapeutics, Inc. (DFTX) vs Scholar Rock Holding Corporation (SRRK)
A side-by-side comparison of Definium Therapeutics, Inc. and Scholar Rock Holding Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DFTX
Definium Therapeutics, Inc.
$35.29HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT
SRRK
Scholar Rock Holding Corporation
$43.03HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT
Total return — DFTX vs SRRK
growth of $100 · dividends reinvested · last 8yDFTX +1468.4% (+41.1%/yr)SRRK +180.0% (+13.7%/yr)DFTX compounded faster over this window
Log scale — wide-divergence pair
DFTX SRRK
DFTX vs SRRK: by the numbers
- •SRRK is the larger company ($5.16B vs $4.68B market cap).
Metrics side by side
Valuation
| Metric | DFTX | SRRK |
|---|---|---|
| P/B ratio | 5.10 | 20.32 |
Profitability
| Metric | DFTX | SRRK |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -38.51% | -161.00% |
| ROIC | -23.81% | -90.04% |
Growth (annualized)
| Metric | DFTX | SRRK |
|---|---|---|
| Total return CAGR (5Y) | 1.43% | 8.20% |
Frequently asked
- How have DFTX and SRRK total returns compared?
- Over the past 5 years, DFTX delivered 1.43% and SRRK delivered 8.20% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.